Modelling the Cost Effectiveness of Antidepressant Treatment in Primary Care

PharmacoEconomics

Volumn 8, Issue 6, 1995, Pages 524-540

  Revicki, Dennis A ^a   Brown, Ruth E ^a   Palmer, Wilfred ^b   Bakish, David ^c   Rosser, Walter W ^b   Anton, Susan F ^d   Feeny, David ^e  

^a MEDTAP International   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; NEFAZODONE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DEPRESSION; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MODEL; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COMPARATIVE STUDY; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMAN; IMIPRAMINE; MARKOV CHAINS; MODELS, ECONOMIC; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TRIAZOLES;

EID: 0028789056     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199508060-00007     Document Type: Article

References (64)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey
2. The functioning and well-being of depressed patients: results from the medical outcomes study
3. Service utilization and social morbidity associated with depressive symptoms in the community
4. Depression, disability days and days lost from work in a prospective epidemiologic survey
5. Psychiatric diagnoses of medical service users: evidence from the epidemiologic catchment area program
6. Utilization of health and mental health services: three epidemiologic catchment sites
7. The economic burden of depression in 1990
8. Prescribing of psychotropic medication by primary care physicians and psychiatrists
9. The hidden mental health network: treatment of mental illness by nonpsychiatrist physicians
10. Patterns of anti-depressant use in community practice
11. The pharmacologic treatment of depression
12. Current status of antidepressants: clinical pharmacology and therapy
13. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability
14. The prophylactic efficacy of fluoxetine and unipolar depression
15. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder
16. Sertraline: a new antidepressant
17. Sertraline in the prevention of depression
18. Nefazodone: preclinical pharmacology of a new antidepressant
19. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression
20. Nefazodone and imipramine in major depression: a placebo-controlled trial
21. Response of anxiety and agitation symptoms during nefazodone treatment of major depression
22. Double-blind comparison of nefazodone, imipramine and placebo in major depression
23. A double-blind, placebo controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients
24. Long-term treatment with nefazodone
25. Comparison of the tolerability of nefazodone, imipramine, fluoxetine, senraline, paroxetine, and venlafaxine
26. The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects
27. Clinical economics: a guide to the economic analysis of clinical practices
28. Cost-utility analysis of maintenance treatment for recurrent depression: a theoretical framework and numerical illustration
29. Cost utility of maintenance treatment of recurrent depression with senraline versus episodic treatment with dothiepin
30. What price depression
31. Measurement of health utilities for economic appraisal: a review
32. Utilities and quality-adjusted life years
33. Medical progress’ decision analysis
34. Consensus methods: characteristics and guidelines for use
35. Relapse in major depressive disorder: analysis with life tables
36. Mood disorders: pharmacologic prevention of recurrence
37. Relapse after recovery from unipolar depression: a critical review
38. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination
39. Time to recovery, chronicity, and levels of psychopathology in major depression: a five-year prospective follow-up of 431 subjects
40. Three-year outcomes for maintenance therapies in recurrent depression
41. Five-year outcome for maintenance therapies in recurrent depression
42. Antidepressant medications and the relative risk of suicide attempt and suicide
43. The assessment and treatment of patients of risk for suicide
44. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta analysis
45. A study of the use of antidepressant medication in general practice
46. The treatment of depression in general practice
47. Depressive disorder in primary care
48. Adequacy and duration of antidepressant treatment in primary care
49. The role of the primary care physician in patients’ adherence to antidepressant therapy
50. How attractive does a new technology have to be to warrant adoption and utilization
51. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
52. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals
53. How can care for depression become more cost-effective
54. Health care costs associated with depressive and anxiety disorders in primary care
55. Methodology for measuring health-state preferences: III. Population and context effects
56. The utility of different health states as perceived by the general public